The current standard of care for dosing–body surface area (BSA)–does not account for many of the factors that impact 5-FU metabolism and efficacy. Some of these factors include genotype, age, gender, disease state, drug-drug interactions, organ function, and comorbidities. Despite its widespread use, BSA accounts for only 2 of these factors–height and weight.1
A recent study showed that up to 85% of patients may not be dosed optimally.2,3*
With optimized dosing, there are proven benefits for both efficacy and toxicity2
- Optimized dosing provided significantly greater objective response rates (33.7% versus 17.3% with BSA-based dosing; P=.004)2
- Despite having higher mean doses of 5-FU,† patients experienced significantly less toxicity (P=.003)2
- Patients experienced a 78% reduction in grades 3/4 diarrhea2
- Optimized dosing demonstrated a trend toward incresed median survival2
- 22 months versus 16 months with BSA-based dosing (P=.08)2
OnDose provides a report that gives you the data you need to help optimize your patient's infusional 5-FU dose. Using the supplied OnDose data, you can make dose adjustments of infusional 5-FU to help optimize therapy for your patient's next cycle of chemotherapy and help maximize efficacy and minimize toxicity.
*Based on data underlying Gamelin et al.
†1500 mg/m2 with BSA-based dosing versus mean of 1790 mg/m2 with optimized dosing.2
References: 1. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990;8(10):1739-1753. 2. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099-2105. 3. Data on file, Myriad Genetic Laboratories, Inc., Salt Lake City, UT. 4. Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer–status of the art. Crit Rev Oncol Hematol. 1999;30(1):71-79.
